Proteasome and cancer

Progress in Molecular Biology and Translational Science

Volumn 109, Issue , 2012, Pages 277-293

  Catalgol, Betul ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bortezomib; Cancer; Proteasome; Transcription factors

Indexed keywords

EID: 84862736944     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397863-9.00008-0     Document Type: Chapter

References (133)

1. J.J. Turner, A.M. Hughes, A. Kricker, S. Milliken, A. Grulich, and J. Kaldor Use of the WHO lymphoma classification in a population-based epidemiological study Ann Oncol 15 2004 631 637 (Pubitemid 38559601)
2. T. Hideshima, P. Richardson, D. Chauhan, V.J. Palombella, P.J. Elliott, and J. Adams The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 2001 3071 3076 (Pubitemid 32691956)
3. O. Coux, K. Tanaka, and A.L. Goldberg Structure and functions of the 20S and 26S proteasomes Annu Rev Biochem 65 1996 801 847 (Pubitemid 26255262)
4. N. Shimbara, E. Orino, S. Sone, T. Ogura, M. Takashina, and M. Shono Regulation of gene expression of proteasomes (multi-protease complexes) during growth and differentiation of human hematopoietic cells J Biol Chem 267 1992 18100 18109
5. H. Kanayama, K. Tanaka, M. Aki, S. Kagawa, H. Miyaji, and M. Satoh Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells Cancer Res 51 1991 6677 6685
6. K.L. Rock, I.A. York, T. Saric, and A.L. Goldberg Protein degradation and the generation of MHC class I-presented peptides Adv Immunol 80 2002 1 70 (Pubitemid 34625620)
7. J. Pallares-Trujillo, N. Carbo, F.J. Lopez-Soriano, and J.M. Argiles Does the mechanism responsible for TNF-mediated insulin resistance involve the proteasome? Med Hypotheses 54 2000 565 569 (Pubitemid 30311544)
8. B.M. Machiels, M.E. Henfling, W.L. Gerards, J.L. Broers, H. Bloemendal, and F.C. Ramaekers Detailed analysis of cell cycle kinetics upon proteasome inhibition Cytometry 28 1997 243 252 (Pubitemid 27294713)
9. S.A. Shah, M.W. Potter, T.P. McDade, R. Ricciardi, R.A. Perugini, and P.J. Elliott 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer J Cell Biochem 82 2001 110 122
10. W. Seufert, B. Futcher, and S. Jentsch Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins Nature 373 1995 78 81
11. M. Pagano, S.W. Tam, A.M. Theodoras, P. Beerromero, G. Delsal, and V. Chau Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor P27 Science 269 1995 682 685
12. G. Martinelli, P. Tosi, E. Ottaviani, S. Soverini, and S. Tura Molecular therapy for multiple myeloma Haematologica 86 2001 908 917 (Pubitemid 32937699)
13. T. Hideshima, D. Chauhan, K. Podar, R.L. Schlossman, P. Richardson, and K.C. Anderson Novel therapies targeting the myeloma cell and its bone marrow microenvironment Semin Oncol 28 2001 607 612 (Pubitemid 33134420)
14. J.B. Almond, R.T. Snowden, A. Hunter, D. Dinsdale, K. Cain, and G.M. Cohen Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an similar to 700 kDa Apaf-1 containing apoptosome complex Leukemia 15 2001 1388 1397 (Pubitemid 32785308)
15. F. Pajonk, K. Pajonk, and W.H. McBride Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition Int J Radiat Oncol Biol Phys 47 2000 1025 1032 (Pubitemid 30345603)
16. D. Schenkein Proteasome inhibitors in the treatment of B-cell malignancies Clin Lymphoma 3 2002 49 55
17. E. Tani, H. Kitagawa, H. Ikemoto, and T. Matsumoto Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells FEBS Lett 504 2001 53 58 (Pubitemid 32777811)
18. H. Oyaizu, Y. Adachi, T. Okumura, M. Okigaki, N. Oyaizu, and S. Taketani Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line Oncol Rep 8 2001 825 829
19. J.L. Herrmann, F. Briones, S. Brisbay, C.J. Logothetis, and T.J. McDonnell Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 Oncogene 17 1998 2889 2899 (Pubitemid 29010059)
20. E.G. Mimnaugh, M.K. Yunmbam, Q.D. Li, P. Bonvini, S.G. Hwang, and J. Trepel Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors Biochem Pharmacol 60 2000 1343 1354
21. X.M. Fan, B.C.Y. Wong, W.P. Wang, X.M. Zhou, C.H. Cho, and S.T. Yuen Inhibition of proteasome function induced apoptosis in gastric cancer Int J Cancer 93 2001 481 488 (Pubitemid 32701406)
22. R.J. Bold, S. Virudachalam, and D.J. McConkey Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome J Surg Res 100 2001 11 17 (Pubitemid 32802698)
23. D.S. Lind, S.N. Hochwald, J. Malaty, S. Rekkas, P. Hebig, and G. Mishra Nuclear factor-kappa B is upregulated in colorectal cancer Surgery 130 2001 363 369 (Pubitemid 32721692)
24. G. Kroemer Mitochondrial control of apoptosis Bull Acad Natl Med 185 2001 1135 1143
25. S. Dimmeler, K. Breitschopf, J. Haendeler, and A.M. Zeiher Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway J Exp Med 189 1999 1815 1822 (Pubitemid 29272698)
26. B. Li, and Q.P. Dou Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression Proc Natl Acad Sci U S A 97 2000 3850 3855 (Pubitemid 30226050)
27. V. Marshansky, X. Wang, R. Bertrand, H. Luo, W. Duguid, and G. Chinnadurai Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells J Immunol 166 2001 3130 3142 (Pubitemid 33117310)
28. K. Breitschopf, A.M. Zeiher, and S. Dimmeler Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction J Biol Chem 275 2000 21648 21652 (Pubitemid 30481872)
29. X.M. Zhang, H. Lin, C. Chen, and B.D. Chen Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells Biochem J 340 Pt 1 1999 127 133 (Pubitemid 29251099)
30. V.A. Soldatenkov, and A. Dritschilo Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins Cancer Res 57 1997 3881 3885 (Pubitemid 27427668)
31. D. Soligo, F. Servida, D. Delia, E. Fontanella, G. Lamorte, and L. Caneva The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI Br J Haematol 113 2001 126 135 (Pubitemid 32423313)
32. H.C. Drexler Activation of the cell death program by inhibition of proteasome function Proc Natl Acad Sci U S A 94 1997 855 860 (Pubitemid 27074411)
33. Y. Yamada, K. Sugahara, K. Tsuruda, K. Nohda, N. Mori, and T. Hata Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines Eur J Haematol 64 2000 315 322 (Pubitemid 30307703)
34. S.T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D.J. McConkey The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts Mol Cancer Ther 3 2004 59 70 (Pubitemid 39193679)
35. R. Ge, Z. Wang, Q. Zeng, X. Xu, and A.F. Olumi F-box protein 10, an NF-kappaB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway Cell Death Differ 18 2011 1184 1195
36. X. Feng, J. Yan, Y. Wang, J.R. Zierath, M. Nordenskjold, and J.I. Henter The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells Mol Immunol 47 2010 2388 2396
37. H. Kashkar, C. Haefs, H. Shin, S.J. Hamilton-Dutoit, G.S. Salvesen, and M. Kronke XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells J Exp Med 198 2003 341 347 (Pubitemid 36987859)
38. H. Kashkar, A. Deggerich, J.M. Seeger, B. Yazdanpanah, K. Wiegmann, and D. Haubert NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs Blood 109 2007 3982 3988 (Pubitemid 46641751)
39. A.J. Levine, J. Momand, and C.A. Finlay The p53 tumour suppressor gene Nature 351 1991 453 456 (Pubitemid 21896613)
40. A. Ciechanover, J.A. DiGiuseppe, B. Bercovich, A. Orian, J.D. Richter, and A.L. Schwartz Degradation of nuclear oncoproteins by the ubiquitin system in vitro Proc Natl Acad Sci U S A 88 1991 139 143 (Pubitemid 21914443)
41. C.G. Maki, J.M. Huibregtse, and P.M. Howley In vivo ubiquitination and proteasome-mediated degradation of p53(1) Cancer Res 56 1996 2649 2654 (Pubitemid 26170702)
42. M. Scheffner, and N.J. Whitaker Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system Semin Cancer Biol 13 2003 59 67 (Pubitemid 36269181)
43. M. Rolfe, P. Beer-Romero, S. Glass, J. Eckstein, I. Berdo, and A. Theodoras Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP) Proc Natl Acad Sci U S A 92 1995 3264 3268
44. R.K. Anchoori, S.R. Khan, T. Sueblinvong, A. Felthauser, Y. Iizuka, and R. Gavioli Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells PLoS One 6 2011 e23888
45. Y. Yuan, Y.M. Liao, C.T. Hsueh, and H.R. Mirshahidi Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP J Hematol Oncol 4 2011 16
46. L. Raycroft, H.Y. Wu, and G. Lozano Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene Science 249 1990 1049 1051
47. T. Miyashita, M. Harigai, M. Hanada, and J.C. Reed Identification of a p53-dependent negative response element in the bcl-2 gene Cancer Res 54 1994 3131 3135 (Pubitemid 24208916)
48. E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev Down-regulation of beta-catenin by activated p53 Mol Cell Biol 21 2001 6768 6781
49. A. Roberti, F. Rizzolio, C. Lucchetti, L.L. de, and A. Giordano Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines Cell Cycle 10 2011 127 134
50. I. Jariel-Encontre, C. Salvat, A.M. Steff, M. Pariat, C. Acquaviva, and O. Furstoss Complex mechanisms for c-fos and c-jun degradation Mol Biol Rep 24 1997 51 56 (Pubitemid 27269426)
51. I. Stancovski, H. Gonen, A. Orian, A.L. Schwartz, and A. Ciechanover Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes Mol Cell Biol 15 1995 7106 7116
52. R.W. McMurray, K. Ndebele, K.J. Hardy, and J.K. Jenkins 17-beta-estradiol suppresses IL-2 and IL-2 receptor Cytokine 14 2001 324 333
53. A. Mori, O. Kaminuma, K. Ogawa, H. Okudaira, and K. Akiyama Transcriptional regulation of IL-5 gene by nontransformed human T cells through the proximal promoter element Intern Med 39 2000 618 625
54. G. Melino, F. Bernassola, M.V. Catani, A. Rossi, M. Corazzari, and S. Sabatini Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation Cancer Res 60 2000 2377 2383 (Pubitemid 30262426)
55. A. Behren, C. Simon, R.M. Schwab, E. Loetzsch, S. Brodbeck, and E. Huber Papillomavirus E2 protein induces expression of the matrix metalloproteinase-9 via the extracellular signal-regulated kinase/activator protein-1 signaling pathway Cancer Res 65 2005 11613 11621 (Pubitemid 41821721)
56. F. Verrecchia, L. Vindevoghel, R.J. Lechleider, J. Uitto, A.B. Roberts, and A. Mauviel Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner Oncogene 20 2001 3332 3340 (Pubitemid 32588981)
57. W. Li, X. Zhang, and A.F. Olumi MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L) Cancer Res 67 2007 2247 2255 (Pubitemid 46424244)
58. M. Lauricella, S. Emanuele, A. D'Anneo, G. Calvaruso, B. Vassallo, and D. Carlisi JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways Apoptosis 11 2006 607 625
59. P.A. Baeuerle, and T. Henkel Function and activation of NF-kappa B in the immune system Annu Rev Immunol 12 1994 141 179
60. R. Sen, and D. Baltimore Multiple nuclear factors interact with the immunoglobulin enhancer sequences Cell 46 1986 705 716 (Pubitemid 16020062)
61. J. Wu On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants Am J Transplant 2 2002 904 912 (Pubitemid 36330219)
62. K. Brown, S. Gerstberger, L. Carlson, G. Franzoso, and U. Siebenlist Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation Science 267 1995 1485 1488
63. C.M. Fan, and T. Maniatis Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway Nature 354 1991 395 398 (Pubitemid 21896848)
64. S.A. Schwartz, A. Hernandez, and E.B. Mark The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies Surg Oncol 8 1999 143 153
65. G. Mosialos The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription Semin Cancer Biol 8 1997 121 129 (Pubitemid 27412328)
66. G. Xiao, M.E. Cvijic, A. Fong, E.W. Harhaj, M.T. Uhlik, and M. Waterfield Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha EMBO J 20 2001 6805 6815 (Pubitemid 33134210)
67. J. Houldsworth, S. Mathew, P.H. Rao, K. Dyomina, D.C. Louie, and N. Parsa REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma Blood 87 1996 25 29 (Pubitemid 26011815)
68. P.H. Rao, J. Houldsworth, K. Dyomina, N.Z. Parsa, J.C. Cigudosa, and D.C. Louie Chromosomal and gene amplification in diffuse large B-cell lymphoma Blood 92 1998 234 240 (Pubitemid 28303198)
69. A. Neri, N.S. Fracchiolla, E. Roscetti, S. Garatti, D. Trecca, and A. Boletini Molecular analysis of cutaneous B- and T-cell lymphomas Blood 86 1995 3160 3172
70. E. Cabannes, G. Khan, F. Aillet, R.F. Jarrett, and R.T. Hay Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha Oncogene 18 1999 3063 3070 (Pubitemid 29261226)
71. B. Jungnickel, A. Staratschek-Jox, A. Brauninger, T. Spieker, J. Wolf, and V. Diehl Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma J Exp Med 191 2000 395 402
72. J.Y. Reuther, G.W. Reuther, D. Cortez, A.M. Pendergast, and A.S. Baldwin Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation Genes Dev 12 1998 968 981 (Pubitemid 28204604)
73. T. Mukhopadhyay, J.A. Roth, and S.A. Maxwell Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma Oncogene 11 1995 999 1003
74. M.A. Sovak, R.E. Bellas, D.W. Kim, G.J. Zanieski, A.E. Rogers, and A.M. Traish Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer J Clin Invest 100 1997 2952 2960 (Pubitemid 28022831)
75. A. Nair, M. Venkatraman, T.T. Maliekal, B. Nair, and D. Karunagaran NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix Oncogene 22 2003 50 58 (Pubitemid 36152883)
76. P.C. Cogswell, D.C. Guttridge, W.K. Funkhouser, and A.S. Baldwin Jr. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3 Oncogene 19 2000 1123 1131 (Pubitemid 30157541)
77. N.J. Thornburg, R. Pathmanathan, and N. Raab-Traub Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma Cancer Res 63 2003 8293 8301 (Pubitemid 37549481)
78. R.L. Shattuck-Brandt, and A. Richmond Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells Cancer Res 57 1997 3032 3039 (Pubitemid 27315057)
79. W. Wang, J.L. Abbruzzese, D.B. Evans, L. Larry, K.R. Cleary, and P.J. Chiao The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin Cancer Res 5 1999 119 127 (Pubitemid 29045184)
80. R. Visconti, J. Cerutti, S. Battista, M. Fedele, F. Trapasso, and K. Zeki Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression Oncogene 15 1997 1987 1994
81. M. Sumitomo, M. Tachibana, C. Ozu, H. Asakura, M. Murai, and M. Hayakawa Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression Hum Gene Ther 10 1999 37 47 (Pubitemid 29046144)
82. S. Amit, and Y. Ben-Neriah NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach Semin Cancer Biol 13 2003 15 28 (Pubitemid 36269177)
83. C. Tan, and T.A. Waldmann Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia Cancer Res 62 2002 1083 1086 (Pubitemid 34160291)
84. D.J. Van Antwerp, S.J. Martin, T. Kafri, D.R. Green, and I.M. Verma Suppression of TNF-alpha-induced apoptosis by NF-kappaB Science 274 1996 787 789
85. D.C. Duffey, Z. Chen, G. Dong, F.G. Ondrey, J.S. Wolf, and K. Brown Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo Cancer Res 59 1999 3468 3474 (Pubitemid 29334510)
86. C.Y. Wang, J.C. Cusack Jr., R. Liu, and A.S. Baldwin Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB Nat Med 5 1999 412 417 (Pubitemid 29180579)
87. A. Yaron, H. Gonen, I. Alkalay, A. Hatzubai, S. Jung, and S. Beyth Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase EMBO J 16 1997 6486 6494 (Pubitemid 27483274)
88. C.C. Chen, C.L. Rosenbloom, D.C. Anderson, and A.M. Manning Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation J Immunol 155 1995 3538 3545
89. F. Pajonk, and W.H. McBride The proteasome in cancer biology and treatment Radiat Res 156 2001 447 459 (Pubitemid 33027513)
90. A.M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, and H. Yasui Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Res 66 2006 184 191 (Pubitemid 43166024)
91. A. Kikuchi, S. Kishida, and H. Yamamoto Regulation of Wnt signaling by protein-protein interaction and post-translational modifications Exp Mol Med 38 2006 1 10 (Pubitemid 43352428)
92. A. Wodarz, and R. Nusse Mechanisms of Wnt signaling in development Annu Rev Cell Dev Biol 14 1998 59 88 (Pubitemid 29001449)
93. J.R. Miller, and R.T. Moon Signal transduction through beta-catenin and specification of cell fate during embryogenesis Genes Dev 10 1996 2527 2539 (Pubitemid 26357220)
94. P.J. Morin, A.B. Sparks, V. Korinek, N. Barker, H. Clevers, and B. Vogelstein Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 1997 1787 1790 (Pubitemid 27136715)
95. J. Behrens, J.P. von Kries, M. Kuhl, L. Bruhn, D. Wedlich, and R. Grosschedl Functional interaction of beta-catenin with the transcription factor LEF-1 Nature 382 1996 638 642 (Pubitemid 26268958)
96. O. Huber, R. Korn, J. McLaughlin, M. Ohsugi, B.G. Herrmann, and R. Kemler Nuclear localization of beta-catenin by interaction with transcription factor LEF-1 Mech Dev 59 1996 3 10 (Pubitemid 26325455)
97. T.C. He, A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, and L.T. da Costa Identification of c-MYC as a target of the APC pathway Science 281 1998 1509 1512 (Pubitemid 28425575)
98. M. Shtutman, J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, and R. Pestell The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway Proc Natl Acad Sci U S A 96 1999 5522 5527 (Pubitemid 29234650)
99. O. Tetsu, and F. McCormick Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 1999 422 426 (Pubitemid 29180374)
100. Y.S. Bian, M.C. Osterheld, F.T. Bosman, C. Fontolliet, and J. Benhattar Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus Am J Clin Pathol 114 2000 583 590 (Pubitemid 33044398)
101. P. Polakis The oncogenic activation of beta-catenin Curr Opin Genet Dev 9 1999 15 21
102. L.C. Cooper, E. Prinsloo, A.L. Edkins, and G.L. Blatch Hsp90alpha/beta associates with the GSK3beta/axin1/phospho-beta-catenin complex in the human MCF-7 epithelial breast cancer model Biochem Biophys Res Commun 413 2011 550 554
103. F. Hofmann, F. Martelli, D.M. Livingston, and Z. Wang The retinoblastoma gene product protectsE2F-1 from degradation by the ubiquitin-proteasome pathway Genes Dev 10 1996 2949 2959 (Pubitemid 26412522)
104. S.N. Boyer, D.E. Wazer, and V. Band E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway Cancer Res 56 1996 4620 4624 (Pubitemid 26338060)
105. H. Higashitsuji, K. Itoh, T. Nagao, S. Dawson, K. Nonoguchi, and T. Kido Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas Nat Med 6 2000 96 99 (Pubitemid 30048534)
106. R.F. Kalejta, and T. Shenk Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp 71 protein Proc Natl Acad Sci U S A 100 2003 3263 3268 (Pubitemid 36356571)
107. J.S. Knight, N. Sharma, and E.S. Robertson Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase Proc Natl Acad Sci U S A 102 2005 18562 18566 (Pubitemid 43011265)
108. P. Sdek, H. Ying, D.L. Chang, W. Qiu, H. Zheng, and R. Touitou MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein Mol Cell Biol 20 2005 699 708 (Pubitemid 41740692)
109. C.G. Li, J.E. Nyman, A.W. Braithwaite, and M.R. Eccles PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein Oncogene 30 2011 4824 4834
110. K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, and L. Dick Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell 78 1994 761 771 (Pubitemid 24294452)
111. E.K. Hoffman, H.M. Wilcox, R.W. Scott, and R. Siman Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis J Neurol Sci 139 1996 15 20 (Pubitemid 26246274)
112. S. Gross-Mesilaty, J.L. Hargrove, and A. Ciechanover Degradation of tyrosine aminotransferase (TAT) via the ubiquitin-proteasome pathway FEBS Lett 405 1997 175 180 (Pubitemid 27136506)
113. J. Adams, V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, and D.D. Lazarus Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 1999 2615 2622 (Pubitemid 29269108)
114. J. Adams Development of the proteasome inhibitor PS-341 Oncologist 7 2002 9 16 (Pubitemid 34151104)
115. M. Pervan, F. Pajonk, J.R. Sun, H.R. Withers, and W.H. McBride Molecular pathways that modify tumor radiation response Am J Clin Oncol 24 2001 481 485 (Pubitemid 32959106)
116. B.A. Teicher, G. Ara, R. Herbst, V.J. Palombella, and J. Adams The proteasome inhibitor PS-341 in cancer therapy Clin Cancer Res 5 1999 2638 2645 (Pubitemid 29437352)
117. Q.Q. Li, M.K. Yunmbam, X. Zhong, J.J. Yu, E.G. Mimnaugh, and L. Neckers Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression Cell Mol Biol (Noisy-le-grand) 47 2001 OL61 OL72 [Online Pub]
118. E.G. Mimnaugh, H.Y. Chen, J.R. Davie, J.E. Celis, and L. Neckers Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response Biochemistry 36 1997 14418 14429 (Pubitemid 27509934)
119. K. Ohkawa, T. Asakura, K. Takada, T. Sawai, Y. Hashizume, and Y. Okawa Calpain inhibitor causes accumulation of ubiquitinated P-glycoprotein at the cell surface: possible role of calpain in P-glycoprotein turnover Int J Oncol 15 1999 677 686
120. T. Kato, D.C. Duffey, F.G. Ondrey, G. Dong, Z. Chen, and J.A. Cook Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB Head Neck 22 2000 748 759
121. S.M. Russo, J.E. Tepper, A.S. Baldwin Jr., R. Liu, J. Adams, and P. Elliott Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB Int J Radiat Oncol Biol Phys 50 2001 183 193
122. J.F. Kurland, and R.E. Meyn Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells Int J Cancer 96 2001 327 333 (Pubitemid 33136285)
123. J. Wolf, P.G. Richardson, M. Schuster, A. LeBlanc, I.B. Walters, and D.S. Battleman Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series Clin Adv Hematol Oncol 6 2008 755 760
124. P. Richardson New therapies for the treatment of multiple myeloma Clin Adv Hematol Oncol 3 2005 345 346 (Pubitemid 41387352)
125. T. Hideshima, C. Mitsiades, M. Akiyama, T. Hayashi, D. Chauhan, and P. Richardson Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 2003 1530 1534 (Pubitemid 36182530)
126. N. Mitsiades, C.S. Mitsiades, V. Poulaki, D. Chauhan, P.G. Richardson, and T. Hideshima Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications Blood 99 2002 4079 4086 (Pubitemid 35332050)
127. C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan, V. Poulaki, A.L. Kung, and F.E. Davies Antimyeloma activity of heat shock protein-90 inhibition Blood 107 2006 1092 1100 (Pubitemid 43156310)
128. G. Roue, P. Perez-Galan, A. Mozos, M. Lopez-Guerra, S. Xargay-Torrent, and L. Rosich The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 Blood 117 2011 1270 1279
129. S. Jagannath, B.G. Durie, J. Wolf, E. Camacho, D. Irwin, and J. Lutzky Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 2005 776 783 (Pubitemid 40904528)
130. K.C. Anderson Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions Exp Hematol 35 2007 155 162 (Pubitemid 46427993)
131. A. Badros, and N. Gahres Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait Clin Adv Hematol Oncol 3 2005 916 917 (Pubitemid 43168749)
132. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, and D. Irwin A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617 (Pubitemid 36741588)
133. P.G. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer, and T. Facon Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498 (Pubitemid 41007864)